Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The utility of circulating tumor DNA as a prognostic biomarker of radical surgery for metastatic colorectal cancer

ABSTRACT: Interventions: Case series:Nil Primary outcome(s): Allelic frequency of ctDNA Study Design: Case series

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2678167 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

The Role of Serum Circulating Tumor DNA (ctDNA) in Recurrence and Efficacy Evaluation of Colorectal Cancer: a Multi-center, Prospective Study

Project description:Interventions: Case series:Nil Primary outcome(s): Serum Circulating Tumor DNA Study Design: Case series

| 2681844 | ecrin-mdr-crc

Prognostic value of tumor deposits in colorectal cancer: a population-based study

Project description:Interventions: Case series:Nil Primary outcome(s): TDs;Survival;distant metastasis Study Design: Sequential

| 2707011 | ecrin-mdr-crc

A prospective observational study evaluating intestinal microbiome as a biomarker to predict the efficacy and toxicity of BRCA1/2 mutant metastatic castration resistant prostate cancer patietns receiveing PARP inhibitors

Project description:Interventions: case series:Nil Primary outcome(s): ORR;OS;PFS;AE Study Design: Sequential

| 2695487 | ecrin-mdr-crc

Relevance study and prognostic analysis for intestinal flora disorders affecting non-coding RNA networks in patients with advanced lung cancer

Project description:Interventions: Case series:Nil Primary outcome(s): intestinal microecological disorders;blood non-coding RNAs and immune status Study Design: Randomized parallel controlled trial

| 2681498 | ecrin-mdr-crc

The effect of TPN combined with somatostatin in the treatment of chylous leakage after D3 radical resection for colorectal cancer: a Single-center, Prospective, Observational Clinical Trial

Project description:Interventions: case series:Nil Primary outcome(s): volume of drainage;Time to resolution;Time to onset Study Design: Sequential

| 2701903 | ecrin-mdr-crc

Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: correlation with FDG-PET/CT

Project description:Circulating tumor DNA (ctDNA) as a biomarker of disease activity in classic Hodgkin lymphoma (cHL) patients are still not well-defined. By profiling primary tumors and ctDNA, we identified common variants between primary tumors and longitudinal plasma samples in most of the cases, confirming high PBatial and temporal heterogeneity. Though ctDNA analyses mirrored HRS cell genetics overall, the prevalence of variants shows that none of them can be used as a single biomarker. Conversely, the estimation of hGE/mL, based in total ctDNA quantification, reflects disease activity and is almost perfectly correlated with standard parameters such as PET/CT that are associated with refractoriness.

2023-12-18 | GSE244989 | GEO

Genome-wide methylation analysis of cerebrospinal fluid circulating tumor DNA: a new biomarker for recurrent glioblastoma [mRNA-Seq]

Project description:Background: Glioblastoma (GBM) is a common malignancy of the central nervous system (CNS) that is prone to recurrent and has a short survival period. Clinical biomarkers for the diagnosis and prognosis of recurrent GBM are lacking.Methods: We collected 4 cerebrospinal fluid (CSF) samples and 1 normal CSF sample from recurrent GBM, as well as paired tissue samples. Genome-wide methylation profiles of CSF circulating tumor DNA (ctDNA) and tissue mRNA transcription profiles were analyzed, and genes were screened by univariate Cox analysis, Lasso regression analysis, and multivariate Cox analysis by the Chinese Glioma Genome Atlas (CGGA) database. Data analysis and visualization were performed using R software, SPSS software, and Graphpad Prism.Results: By taking the intersection of differentially methylated regions (DMRs) and differentially expressed genes (DEGs), 892 genes were selected for Lasso regression analysis and multivariate Cox analysis, and 12 hub genes were finally screened to construct diagnostic and prognostic models. The diagnostic (AUC=0.982) and prognostic (5-years AUC=0.931) models based on the 12 hub genes had high accuracy.Conclusions: This study reveals that 12 hub genes in CSF ctDNA can diagnose and prognosticate recurrent GBM and provide new biomarkers for clinical research into the mechanisms of GBM recurrent.

2023-05-01 | GSE205512 | GEO

Genome-wide methylation analysis of cerebrospinal fluid circulating tumor DNA: a new biomarker for recurrent glioblastoma [MeDIP-Seq]

2023-05-01 | GSE205513 | GEO

Risk factors of intestinal complications after colorectal surgery

Project description:Interventions: Case series:Nil Primary outcome(s): Intestinal complications Study Design: Case series

| 2680417 | ecrin-mdr-crc

Clinical Utility of Circulating Pentraxin 3 as a Prognostic Biomarker in Coronavirus Disease 2019: A Systematic Review and Meta-analysis.

Project description:IntroductionPentraxin 3 (PTX3) is involved in inflammation regulation and has a certain association with infectious diseases. However, its specific correlation with infectious diseases remains controversial. This study aimed to analyze the association between them and explore the possible role of PTX3 in the prognosis of coronavirus disease 2019 (COVID-19).MethodsFive databases (PubMed, Cochrane Library, Embase, Clinicaltrials.gov, and gray literature) were searched. Outcomes were expressed as a standardized mean difference (SMD) and 95% confidence intervals (CI). The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of included articles. Stata 12 and Meta-DiSc were applied to analyze the pooled data. Receiver operating characteristic (ROC) curves were conducted to determine the prognostic value of PTX3 for mortality.ResultsSix articles met the inclusion criteria. Circulating PTX3 levels had a nonsignificant difference between intensive care unit (ICU) and non-ICU patients with COVID-19 [SMD 1.37 (-0.08, 2.81); I2 = 93.9%, P < 0.01], while the PTX3 levels in nonsurvival COVID-19 patients was significantly lower than those in survival patients [SMD -1.41 (-1.92, -0.91); I2 = 66.4%, P = 0.051]. Circulating PTX3 had good mortality prediction ability (area under ROC curve, AUC = 0.829) in COVID-19. Funnel plots and Egger's tests showed low probabilities of publication bias. Through sensitivity analysis, the results of this study were robust.ConclusionThis study found that PTX3 was differentially expressed between survival and nonsurvival patients with COVID-19, while there was no significant difference between ICU and non-ICU patients. Meanwhile, circulating PTX3 may be a good biomarker for monitoring the prognosis of COVID-19, which may provide new ideas and directions for clinical and scientific research.

| S-EPMC9707160 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data